Dermatology · Autoimmune Disease
The FDA's inclusion of Quinacrine Hydrochloride on the 503B list highlights a regulatory shift that could influence treatment options for cutaneous lupus erythematosus. This may lead to increased competition from compounded products, necessitating a strategic response from pharma companies in the autoimmune space.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/17/2026, 6:32:16 PM
Assessment confidence: 52% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The FDA's inclusion of Quinacrine Hydrochloride on the 503B list highlights a regulatory shift that could influence treatment options for cutaneous lupus erythematosus. This may lead to increased competition from compounded products, necessitating a strategic response from pharma companies in the autoimmune space. Regulatory context from FDA (Compounding Safety Information: Quinacrine Hydrochloride) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).
Pharma companies should consider the implications of compounded drugs on their product offerings and market strategies in the autoimmune space. The strongest clinical anchor is COMPARISON OF INTRALESIONAL GLUCANTIME ALONE VERSUS COMBINED WITH FRACTIONAL CO2 LASER FOR ADULT CUTANEOUS LEISHMANIASIS (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In immunology, 1 regulatory and 4 competitive items passed relevance filtering for AbbVie.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.
Regulatory risk is concentrated around Compounding Safety Information: Quinacrine Hydrochloride (FDA). Entity match (quinacrine hydrochloride). The approval for compounding indicates a recognized clinical need, which may prompt further regulatory scrutiny and influence labeling and compliance for existing therapies.
Compounding Safety Information: Quinacrine Hydrochloride
FDAmedium relevance
Entity match (quinacrine hydrochloride)
FDA document
View sourceFDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCompounding Quality Center of Excellence | Recorded Webinars
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceHuman Drug Compounding
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCompounding Quality Center of Excellence
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCompounding Quality Center of Excellence | Instructor-Led Trainings
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCompounding Quality Center of Excellence | Self-Guided Online Trainings
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCOMPARISON OF INTRALESIONAL GLUCANTIME ALONE VERSUS COMBINED WITH FRACTIONAL CO2 LASER FOR ADULT CUTANEOUS LEISHMANIASIS
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAssessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceDiabetes and Heart Disease Risk in Blacks
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceStrategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEfficacy and Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceFDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalslow relevance
Sponsor/company relevance (Merck)
Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.
PubMedhigh relevance
Sub-indication match (immunology)
FDA document
View sourceSustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedhigh relevance
Sub-indication match (immunology)
FDA document
View sourceSubcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceMicroneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceGinger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe role of protein palmitoylation in disease pathogenesis and therapeutic innovation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's inclusion of Quinacrine Hydrochloride on the 503B list highlights a regulatory shift that could influence treatment options for cutaneous lupus erythematosus. This may lead to increased competition from compounded products, necessitating a strategic response from pharma companies in the autoimmune space.
The emergence of compounded quinacrine products could disrupt existing market dynamics, potentially affecting market share for established therapies in the autoimmune sector.
The approval for compounding indicates a recognized clinical need, which may prompt further regulatory scrutiny and influence labeling and compliance for existing therapies.
Monitor the uptake of quinacrine compounded products and any emerging clinical data on their efficacy and safety.
Track for follow-up milestones; no immediate action required.